ABSTRACT Obesity and comorbid binge eating are serious health problems for more than 40% of adults across the US.7 Health complications due to obesity comprise more than 20% of the nation’s healthcare budget, and the healthcare costs of individuals with binge eating are $18,152 higher than in obese peers without binge eating.13 The prevalence of binge eating and the substantial burden of healthcare costs highlight the need for treatments that eliminate binge eating and produce weight loss. Despite this, there is a paucity of interventions that address these comorbid conditions. In this Phase 1 project, we seek to build a digital therapeutic (called OTX-401) that will be ready for testing in a large, multi-site, well-powered clinical trial during Phase 2. Positive results will be the critical initial step to facilitating the widespread implementation and commercialization of the digital therapeutic to enhance access to highly personalized obesity and binge eating intervention.